Grail
Prezzo: 59.85Società e modello di business
Grail is a healthcare company focused on early cancer detection through advanced genomic testing. Its core products include multi-cancer early detection tests that analyze blood samples to identify various types of cancer at an early stage. The company primarily generates revenue from the sale of these diagnostic tests, targeting both healthcare providers and patients. Grail operates in the diagnostics segment of the healthcare industry, emphasizing innovation in cancer screening technologies.
Profilo di investimento
The investment profile of Grail suggests it may be more suitable for value investors due to its current financial challenges and lack of dividends. The stock's volatility and recent performance indicate a higher risk, which may not appeal to growth-focused investors. A balanced approach could be considered, but the overall outlook leans towards caution.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -10.37 Rischio
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -6.4% ↓
- Sorpresa EPS
- 17.1% meglio del previsto
- Volatilità 20g
- 4.9% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-03 02:42 | Mantieni | Vendi | scenario_deterioration |
| 2026-06-01 02:39 | Vendi | Mantieni | Weak fundamentals and high volatility raise significant concerns. |
| 2026-05-08 15:27 | — | Vendi | Weak fundamentals and high volatility raise significant concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-05 06:33 | Goldman Sachs | Aggiorna | — → 60 | 66.55 |
| 2026-05-06 11:22 | Piper Sandler | Target alzato | 54 → 56 | 54.4 |
| 2026-05-06 10:47 | Robert W. Baird | Target abbassato | 82 → 70 | 54.4 |
Ancora nulla